11 Oct 21

KYMOS at CPhI Worldwide 2021 in Milan

The time for CPhI 2021 Milan is finally here after 2020's hiatus and Kymos is sending an even larger contingent of 12 experts to repeat our success back in CPhI 2019 Frankfurt. Covering every step of the supply chain, CPhI is the perfect place to network and Kymos is an ideal multidisciplinary partner to outsource your pharmaceutical needs. Whether your focus is early drug development and innovator projects or quality control of generics or biosimilars, our latest developments in CMC and bioanalytical services will be relevant for your company.

07 Oct 21

Analytical Development & Validation: The Entry Gate Of Your Project

Rosa Latorre, PhD in Analytical Chemistry and Director of the Analytical Development and Validation Department at Kymos, started her career in big pharmaceutical multinationals such as Merck, Grifols and Ipsen before joining Kymos - which in 2009 was a much smaller CRO than today - to provide analytical services for those global players she had been part of before. Dr. Latorre remembers her beginnings at Kymos:

16 Sep 21

Pharmaprogress’ First-Hand Nitrosamine Experience: Pushing the Analytical Envelope

We are pleased to announce that Dr Luca Gramaccioni, General Site Manager at Kymos Italian Site Pharmaprogress, has been asked to share his analytical experience on nitrosamines in yet another webinar – this time the AFI Symposium 2021 hosted by the Associazione Farmaceutici Industria on September 24th. In anticipation for the event, he and Dr Massimo Bartolacci, Pharmaprogress’ nitrosamine expert, share their insight into how regulatory requirements have evolved since the classification of nitrosamines as probable human carcinogens back in 2019: 

16 Jul 21

Percutaneous Absorption: Like a Second Skin

An important function of the skin is to protect the body from the environment, and it is normally a very effective barrier against external substances. In some cases, however, penetration of active substances (API) into the skin is desired to provide a therapeutic effect. Hence, manufacturers of pharmaceutical topical products must test how well their products penetrate the skin. Dr. Carles Celma, Scientific Director at Kymos, explains how such a task can pose a few challenges: 

28 Jun 21

20 Years Growing Together

Not many companies can celebrate 20 years of collaboration after reporting their best revenues ever and having become a successful multinational group, but contract research organization KYMOS and top biopharmaceutical innovator PHARMAMAR are just going to do that. How the evolution of pharmaceutical outsourcing over the last two decades has changed the trajectory of these two old-time partners is a story worth reading. Kymos’ Co-Founder and Site General Manager Dr. Lluïsa García takes a moment with PharmaMar’s Manager of Nonclinical Toxicology and Pharmacology Dr.

10 May 21

Pharmaprogress’ real-life cases in AEFI symposium Round Table on Nitrosamines

Luca Gramaccioni, Site General Manger at Kymos Pharmaprogress, was a guest speaker at the 40th AEFI symposium last May 11th. He presented “Nitrosamines: How to face the analytical challenges for step 2” at a Round Table alongside other experts from AEMPs, AZIERTA and AGILENT. 
In his presentation Dr. Gramaccioni evaluated the advantages of outsourcing non-routine testing of N-nitrosamine impurities, data requirements from regulatory authorities and showed three real-life case studies taken from daily practice.

26 Apr 21

Your Stability Studies in Safe Hands

In recent years Kymos has experienced a surge in demand from drug manufacturers in need of a reliable outsourcing partner for their stability programmes. Kymos responded by making a major investment to build new climatic chambers in their sites in Spain and Italy to reach today’s 100m³ of storage capacity for all conditions corresponding to ICH zones II, IVb as well as other customized conditions.

16 Apr 21

KYMOS: Adding Value to Biopharma

KYMOS recently had the pleasure to lead a TV program series about the importance of outsourcing service providers like ourselves in the provision of medicines. Since the outbreak of COVID-19 the general public is paying much more attention to the biopharmaceutical industry and the challenges of conducting drug development, manufacturing, quality control and supply in the midst of a global pandemic.